1. Clinical and molecular delineation of the 17q21.31 microdeletion syndrome.
- Author
-
Koolen, D. A., Sharp, A. J., Hurst, J. A., Firth, H. V., Knight, S. J. L., Goldenberg, A., Saugier-Veber, P., Pfundt, A., Vissers, L. E. L. M., Destrée, A., Grisart, B., Rooms, L., Van der Aa, N., Field, M., Hackett, A., Bell, K., Nowaczyk, M. J. M., Mancini, G. M. S., Poddighe, P. J., and Schwartz, C. E.
- Subjects
INTELLECTUAL disabilities ,DEVELOPMENTAL delay ,GENETIC mutation ,OLIGONUCLEOTIDES ,GENETIC polymorphisms ,FUNCTIONAL genomics ,GENETICS - Abstract
Background: The chromosome 1 7q2 1.31 microdeletion syndrome is a novel genomic disorder that has originally been identified using high resolution genome analyses in patients with unexplained mental retardation. Aim: We report the molecular and/or clinical character- isation of 22 individuals with the 17q21.31 microdeletion syndrome. Results: We estimate the prevalence of the syndrome to be 1 in 16 000 and show that it is highly underdiagnosed. Extensive clinical examination reveals that developmental delay, hypotonia, facial dysmorphisms including a long face, a tubular or pear-shaped nose and a bulbous nasal tip, and a friendly/amiable behaviour are the most characteristic features. Other clinically important features include epilepsy, heart defects and kidney/urologic anomalies. Using high resolution oligonucleotide arrays we narrow the 17q21.31 critical region to a 424 kb genomic segment (chr17: 41046729-41470954, hg17) encompassing at least six genes, among which is the gene encoding microtubule associated protein tau (MAPT). Mutation screening of MAPT in 122 individuals with a phenotype suggestive of 17q21.31 deletion carriers, but who do not carry the recurrent deletion, failed to identify any disease associated variants. In five deletion carriers we identify a <500 bp rearrangement hotspot at the proximal breakpoint contained within an L2 LINE motif and show that in every case examined the parent originating the deletion carries a common 900 kb 17q21.31 inversion polymorphism, indicating that this inversion is a necessary factor for deletion to occur (p<105). Conclusion: Our data establish the 17q21.31 micro- deletion syndrome as a clinically and molecularly well recognisable genomic disorder. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF